- Healthcare 150
- Posts
- Healthcare's Capital Is Getting More Selective
Healthcare's Capital Is Getting More Selective
Biopharma IPOs reopen, AI reshapes digital health, and margins come under pressure.
Good morning, ! Today we examine how healthcare is entering a more selective phase—from the reopening of the biopharma IPO market and the concentration of capital in AI-enabled digital health to the growing pressure on provider margins and reimbursement.
As capital becomes more disciplined and operating pressures intensify, the biggest opportunities may belong to the companies improving healthcare's underlying economics—not simply adding another layer of technology.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
DATA DIVE
Revenue Cycle Management Is Becoming a Margin Defense
Revenue cycle management is moving out of the back office.
As reimbursement pressure increases, healthcare providers are facing a difficult combination: lower expected revenue, higher denial rates and slower cash collection. In McKinsey’s survey of US care delivery leaders, 76% expect denial rates to increase, while 74% expect a negative impact on net patient service revenue and 56% expect days in accounts receivable to rise.
The implication is straightforward: getting paid is becoming more difficult — and more expensive.
That is creating a new opening for AI and automation across the revenue cycle. But the opportunity is not simply to automate billing. The larger prize is to connect fragmented workflows, reduce revenue leakage and move RCM from a labor-intensive administrative function toward an increasingly autonomous financial infrastructure layer.
In this week’s Deep Dive, we look at why RCM is becoming a strategic margin defense, what is holding back AI adoption and why the next generation of winners may be the platforms that can orchestrate the entire revenue cycle.
The future of healthcare AI may be clinical. Its first truly scalable financial opportunity could be administrative.
You’re invited: Where AI Meets Private Equity
Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.
On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.
The morning will feature three practitioner-led discussions:
AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.
AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.
Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.
Interested in attending? Register or request the full agenda here
HEALTHTECH CORNER
The Biopharma IPO Window Is Reopening — Selectively
After a prolonged freeze in biotech public markets, the IPO window is showing signs of life. But the recovery remains highly selective.
The key signal is the relationship between total IPO proceeds and deal count. A rebound in capital raised does not necessarily mean a broad reopening of the market. If proceeds rise faster than the number of IPOs, the message is clear: investors are willing to fund companies with stronger clinical data, differentiated platforms and more visible catalysts—but they are not yet willing to fund the sector indiscriminately.
That distinction matters. The next phase of the biopharma IPO market is unlikely to be defined by volume. It will be defined by quality concentration.
For private companies, the bar to go public remains high. For investors, however, a reopening of the IPO market could improve exit visibility and gradually unlock the broader biotech financing cycle.
The bottom line: the biopharma IPO market may be coming back—but this time, the market is choosing the companies, not the other way around.
COMPETITIVE LANDSCAPE SNAPSHOT
TREND TO WATCH
AI Is Repricing Digital Health
Digital health funding is recovering, but the capital is not coming back evenly. In 2025, digital health startups raised $14.2B, up 35% year over year, while AI-enabled companies captured 54% of total funding and commanded an average deal-size premium over non-AI companies. At the same time, deal volume fell, meaning more capital is concentrating in fewer, larger companies.
The important shift is not just that investors are funding AI. It is that AI is increasingly becoming a filter for capital allocation. The companies attracting the largest checks are increasingly those using AI to change the economics of healthcare workflows — from clinical documentation and revenue cycle management to data infrastructure and care delivery.
The implication for healthcare investors and executives is straightforward: the market may be moving from a “digital health” category defined by software adoption to an AI-enabled infrastructure market defined by measurable productivity, margin and workflow gains.
The next question is whether AI is creating a durable new class of healthcare companies — or simply creating a new premium for companies that can attach AI to existing healthcare infrastructure.
